CHMP opinions on consultation procedures

Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 4, Status: Withdrawn (authorisation)

Human medicines European public assessment report (EPAR): MenQuadfi, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 18/11/2020, Revision: 15, Status: Authorised

VidPrevtyn Beta: Periodic safety update report assessment 10 May 2023 to 9 November 2023

Referral: Oxbryta, Voxelotor Article 20 procedures Procedure started

Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 29 July 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 29 July 2024, 10:00 (CEST) to 29 July 2024, 12:00 (CEST)

Human medicines European public assessment report (EPAR): Upstelda, ustekinumab, Status: Withdrawn application (before opinion)

Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 14, Status: Authorised

EMA supports pilot for joint African continental assessment procedures

Human medicines European public assessment report (EPAR): Pemetrexed Krka, pemetrexed, Date of authorisation: 22/05/2018, Revision: 6, Status: Withdrawn (authorisation)